Cat. No.: HY-N5025

Bullatine A

Customer Review

Based on 1 Customer Validation

Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 1354-84-3
Formula: C₂₂H₃₃NO₂
Molecular Weight:343.50

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Bullatine A Chemical Structure

CAS No.: 1354-84-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

P2X7 Receptor

All P2X Receptor Isoforms :

All ERK Isoforms :

All p38 MAPK Isoforms :

All NF-κB Isoforms :

In Vitro

Bullatine A (1-50 μM, 24 h) inhibits ATP-induced BV-2 cell death, down-regulates mRNA levels of IL-6、IL-1β、iNOS, reduces overproduction of NO and IL-6, and selectively inhibits up-regulation of P2X7 receptor mRNA (without effect on P2X4 mRNA) in BV-2 cells^[1]. Bullatine A (1-100 μM, 6 h) dose-dependently stimulates prodynorphin expression in primary microglia with an EC₅₀ of 3.2 μM^[2].
Bullatine A (10-80 μM, 6 h) significantly inhibits LPS (HY-D1056)-induced mRNA expression of IL-1β, IL-6, iNOS and TNF-α in BV2 microglia and iBMDMs^[3].
Bullatine A (80 μM) inhibits LPS-induced IKKα/β、IκBα phosphorylation and NF-κB p65 nuclear translocation, decreases JNK phosphorylation but not p38、ERK1/2 phosphorylation in iBMDMs^[3].
Bullatine A (80 μM, 24 h) reduces LPS-induced intracellular ROS generation in iBMDMs^[3].
Bullatine A (50-800 nM, 7 days) dose-dependently reduces the colony-forming ability of U87MG and U251 cells^[4].
Bullatine A (5-45 μM, 24 h) dose-dependently increases the early and late apoptosis rates of U87MG cells, reduces mitochondrial membrane potential and induces G2/M phase cell cycle arrest in U87MG and U251 cells^[4].
Bullatine A (5-45 μM, 24 h) downregulates p-ERK and Myc and dose-dependently inhibits H3K9Ac、H3K56Ac while upregulating SIRT6 in U87MG cells^[4].
Bullatine A (50 μM, 24 h) inhibits eATP-induced mitochondrial calcium overload, increased ER-mitochondria colocalization, activation of PERK-elF-2α UPR, lysosome production, elevated NLRP3 inflammasome protein expression, and reduced viability in BV-2 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

ATP-induced BV-2 cells
Concentration:

1, 10, 50 μM
Incubation Time:

24 h
Result:

Up-regulated the ratio of Bcl-2/Bax mRNA.
Down-regulated ATP-induced mRNA levels of IL-6, IL-1β and iNOS in BV-2 cells.
Inhibited ATP-induced up-regulation of P2X7 receptor mRNA without obvious effect on P2X4 mRNA in BV-2 cells.

Real Time qPCR^[3]

Cell Line:

LPS-induced BV2 microglia and iBMDMs
Concentration:

10, 20, 40, 80 μM
Incubation Time:

6 h
Result:

Inhibited LPS (HY-D1056)-induced mRNA expression of IL-1β, IL-6, iNOS and TNF-α in BV2 microglia and iBMDMs.

Cell Cycle Analysis^[4]

Cell Line:

U87MG and U251 cells
Concentration:

5, 15, 45 μM
Incubation Time:

24 h
Result:

Induced G2/M phase cell cycle arrest in U87MG and U251 cells.

Apoptosis Analysis^[4]

Cell Line:

U87MG cells
Concentration:

5, 15, 45 μM
Incubation Time:

24 h
Result:

Increased the early and late apoptosis rates of U87MG cells.
Upregulated the expression of cleaved caspase-9, cleaved caspase-3 and Bax.
Downregulated the expression of Bcl-2.

Western Blot Analysis^[4]

Cell Line:

U87MG cells
Concentration:

5, 15, 45 μM
Incubation Time:

24 h
Result:

Downregulated the expression of p-ERK and Myc proteins in U87MG cells.
Inhibitd the expression of H3K9Ac and H3K56Ac in U87MG cells.
Upregulated the expression of SIRT6.

In Vivo

Bullatine A (0.3-30 mg/kg, s.c., cumulative doses at 1 h intervals ) dose-dependently attenuates mechanical allodynia and thermal hyperalgesia in spinal nerve ligation-induced neuropathic rats and Complete Freund’s adjuvant (CFA)-induced inflammatory pain rats^[2].
Bullatine A (0.3-30 mg/kg, s.c., cumulative doses at 1 h intervals ) mitigates mechanical allodynia in Walker 256-induced bone cancer pain rats and Streptozotocin (HY-13753)-induced neuropathic rats^[2].
Bullatine A (0.3-30 μg (10 μL), i.t., single dose) inhibits mechanical allodynia in neuropathic rats^[2].
Bullatine A (5-20 mg/kg, i.p., twice at 12 h and 1 h prior to LPS injection) attenuates LPS-induced systemic inflammatory response in mice^[3].
Bullatine A (10 μg/kg, i.g., once daily, 2 weeks) improves despair behavior in CSDS mice^[5].
Bullatine A (10 μg, intra-hippocampal microinjection, every two days, 10 days) partially ameliorates CSDS-induced depressive-like behaviors in hippocampal MAMs^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Spinal nerve ligation-induced neuropathic pain model: adult male Wistar rats were subjected to tight ligation of left L5 and L6 spinal nerves under isoflurane anesthesia^[2]
Dosage:

0.3, 1, 3, 10, 30 mg/kg
Administration:

s.c. cumulative doses at 1 h intervals
Result:

Attenuated mechanical allodynia and thermal hyperalgesia in spinal nerve ligation-induced neuropathic pain rats, with ED₅₀ of 1.9 mg/kg and 0.7 mg/kg, E_max of 56.6% MPE and 66.1% MPE respectively.

Animal Model:

Diabetic neuropathic pain model: adult male Wistar rats were fasted for 16 h, then received a single intravenous injection of Streptozotocin (40 mg/kg)^[2]
Dosage:

0.3, 1, 3, 10, 30 mg/kg
Administration:

s.c. cumulative doses at 1 h intervals
Result:

Alleviated mechanical allodynia in streptozotocin-induced diabetic neuropathic pain rats, with ED₅₀ of 1.2 mg/kg and E_max of 65.5% MPE.

Animal Model:

Complete Freund’s adjuvant (CFA)-induced inflammatory pain model: 100 μL of CFA was injected into the tibiotarsal joint of the left hindpaw of adult male Wistar rats under mild isoflurane anesthesia^[2]
Dosage:

0.3, 1, 3, 10, 30 mg/kg
Administration:

s.c. cumulative doses at 1 h intervals
Result:

Reduced mechanical allodynia and thermal hyperalgesia in CFA-induced inflammatory pain rats, with ED₅₀ of 1.4 mg/kg and 0.6 mg/kg, E_max of 50.2% MPE and 60.2% MPE respectively.

Animal Model:

Bone cancer pain model: Adult female Wistar rats were anesthetized with intraperitoneal pentobarbital (50 mg/kg), and 4 × 10⁵⁰ Walker 256 carcinoma cells in 10 μL phosphate buffer solution were injected into the medullary cavity of the left tibia^[2]
Dosage:

0.3, 1, 3, 10, 30 mg/kg
Administration:

s.c. cumulative doses at 1 h intervals
Result:

Mitigated mechanical allodynia in bone cancer pain rats induced by tibial implantation of Walker 256 carcinoma cells, with ED₅₀ of 0.9 mg/kg and E_max of 45.6% MPE.

Animal Model:

Spinal nerve ligation-induced neuropathic pain model: adult male Wistar rats were subjected to tight ligation of left L5 and L6 spinal nerves under isoflurane anesthesia^[2]
Dosage:

0.3, 1, 3, 10, 30 μg (10 μL)
Administration:

i.t. for a single dose
Result:

Inhibited mechanical allodynia in neuropathic pain rats, with ED₅₀ of 1.1 μg and E_max of 55.5% MPE.

Animal Model:

C57BL/6 mice (8-10 weeks old, male, 20-25 g) were intraperitoneally injected with 5 mg/kg LPS to induce systemic inflammatory response^[3]
Dosage:

5, 10, 20 mg/kg
Administration:

i.p., twice at 12 h and 1 h prior to LPS injection
Result:

Alleviated LPS-induced liver and lung tissue damage with reduced pathological scores.
Reduced serum IL-6 levels in LPS-treated mice.
Down-regulated mRNA expression of IL-1β, IL-6, iNOS and TNF-α in liver and showed similar trend in lung.
Attenuated immune cell infiltration and structural disruption in liver and lung tissues.

Animal Model:

8-week-old C57BL/6J mice were subjected to chronic social defeat stress (CSDS) for 10 days^[5]
Dosage:

10 μg/kg
Administration:

i.g. once daily for 2 weeks
Result:

Shortened immobility time in forced swimming test (FST) at 10 μg/kg dose, improving despair behavior.
Showed no significant effects on social interaction ratio (SIT), total travel distance in open field test (OFT), or sucrose preference rate (SPT).
Failed to inhibit hippocampal microglia activation induced by CSDS.

Animal Model:

8-week-old C57BL/6J mice underwent hippocampal catheterization surgery, recovered, then were subjected to 10-day CSDS^[5]
Dosage:

10 μg
Administration:

Intra-hippocampal microinjection every two days for 10 days
Result:

Increased social interaction ratio (SIT) and shortened immobility time in FST at 10 μg dose, partially ameliorating depressive-like behaviors.
Showed no significant changes in total travel distance in OFT.
Inhibited the increase of Facl-4 protein in hippocampal mitochondrial-associated ER membranes (MAMs) .
Had no significant effect on other MAMs-related proteins (Sigma-1, VDAC, Mfn2).

Chemical Information

CAS No. 1354-84-3
Appearance Solid
Molecular Weight 343.50
Formula C₂₂H₃₃NO₂
Color White to off-white
SMILES

O[C@H](C1C2([C@@H]3O)C4C[C@]5([H])[C@@]6(C)CCCC51C4N(CC)C6)C(CC2)C3=C
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 12.5 mg/mL (36.39 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9112 mL

14.5560 mL

29.1121 mL

5 mM

0.5822 mL

2.9112 mL

5.8224 mL

10 mM

0.2911 mL

1.4556 mL

2.9112 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (300 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li J, et al. Bullatine A, a diterpenoid alkaloid of the genus Aconitum, could attenuate ATP-induced BV-2 microglia death/apoptosis via P2X receptor pathways. Brain Res Bull. 2013 Aug;97:81-5. [Content Brief]

[2]. Huang Q, et al. Bullatine A stimulates spinal microglial dynorphin A expression to produce anti-hypersensitivity in a variety of rat pain models. J Neuroinflammation. 2016 Aug 30;13(1):214. [Content Brief]

[3]. Liu S, et al. Bullatine A exerts anti-inflammatory effects by inhibiting the ROS/JNK/NF-κB pathway and attenuating systemic inflammatory responses in mice. Pharm Biol. 2022 Dec;60(1):1840-1849. [Content Brief]

[4]. Wang Z, et al. Bullatine A suppresses glioma cell growth by targeting SIRT6. Heliyon. 2024 Dec 24;11(1):e41440. [Content Brief]

[5]. Zhang JR, et al. Bullatine A has an antidepressant effect in chronic social defeat stress mice; Implication of microglial inflammasome. Brain Res Bull. 2023 Apr;195:130-140. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9112 mL	14.5560 mL	29.1121 mL	72.7802 mL
	5 mM	0.5822 mL	2.9112 mL	5.8224 mL	14.5560 mL
	10 mM	0.2911 mL	1.4556 mL	2.9112 mL	7.2780 mL
	15 mM	0.1941 mL	0.9704 mL	1.9408 mL	4.8520 mL
	20 mM	0.1456 mL	0.7278 mL	1.4556 mL	3.6390 mL
	25 mM	0.1164 mL	0.5822 mL	1.1645 mL	2.9112 mL
	30 mM	0.0970 mL	0.4852 mL	0.9704 mL	2.4260 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Bullatine A

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Neurotransmitter Receptor Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

All P2X Receptor Isoforms

All ERK Isoforms

All p38 MAPK Isoforms

All NF-κB Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References